Dr. Erez Bublil is Orphan Technologies’ Vice President of Research and Development. In his capacity, he initiates and overseas the design, development, execution and implementation of research and development projects and executes both basic and applied research to build, support and extend Orphan Technologies’ innovative portfolio. Dr. Bublil Joined Orphan Technologies in 2014, and brings 20 years of research experience in the academia. He has authored manuscripts and reviews in peer reviewed journals, authored book chapters, and has several patents to his name.
Before joining Orphan Technologies, Dr. Bublil served as a scientist at the University of Colorado Denver, where he was instrumental to the research on Orphan’s lead drug candidate, OT-58. Dr. Bublil earned his B.Sc. (Magna Cum Laude) and M.Sc. (Summa Cum Laude) from Tel-Aviv University, focusing on cancer therapeutics. He earned his PhD in Cell Research and immunology from Tel-Aviv University focusing on rational design of HIV vaccines. His postdoc studies were carried out at the Weizmann Institute of Science at the prestigious laboratory of Prof. Yosef Yarden, where he focused on signal transduction in cancer, and development of anti-cancer therapeutics.